BioCentury | Sep 4, 2020
Product Development

Rain to advance growing precision oncology pipeline with $63M series B

A crossover-heavy $63 million series B round will provide Rain with enough money to bring what it says is its new lead program — a newly licensed cancer therapy from Daiichi Sankyo — through clinical proof of...
BioCentury | Aug 18, 2020
Product Development

Unity outlines path forward for anti-aging programs after Phase II osteoarthritis failure

After the failure of its lead anti-aging program in osteoarthritis, Unity believes more objective clinical endpoints and robust preclinical data for its next-in-line ophthalmology candidate mean that program won’t suffer the same fate in the...
BioCentury | Jul 29, 2020
Distillery Therapeutics

Promoting degradation of the MDM2 oncogene for liposarcoma

DISEASE CATEGORY: Cancer INDICATION: Sarcoma A pyrido-indole-based tool compound that triggers degradation of MDM2, an enzyme that suppresses p53 expression, could treat liposarcoma. In 10 human liposarcoma cell lines, the compound inhibited growth with IC...
BioCentury | Apr 23, 2020
Product Development

Roche reveals trial failures

Along with its 1Q20 earnings, Roche disclosed negative readouts in three clinical trials. Following a futility analysis, Roche (SIX:ROG; OTCQX:RHHBY) stopped the Phase III V1aduct trial of V1a receptor antagonist balovaptan (RG7314) to treat adults...
BioCentury | Jan 10, 2020
Product Development

Seeking structural endpoints for OA

As the first disease-modifying therapies for osteoarthritis enter late-stage development, companies are testing new endpoints that can capture effects on joint structure instead of relying on traditional pain-related readouts. Most are converging on MRI imaging...
BioCentury | Sep 6, 2019
Emerging Company Profile

Cullgen: boosting the breadth of E3 ligases for protein degradation

Cullgen is expanding the toolbox of E3 ubiquitin ligases that can be used to target and degrade cancer-associated proteins by looking beyond widely used ligases. With its ubiquitin-mediated, small molecule-induced targeted elimination (uSMITE) technology, Cullgen...
BioCentury | Aug 29, 2019
Distillery Therapeutics

Boosting cancer sensitivity to CDK4, CDK6 inhibitors by inhibiting the PRMT5-MDM4 axis

...DISEASE CATEGORY: Cancer INDICATION: Melanoma; breast cancer; esophageal cancer; pancreatic cancer Inhibiting the PRMT5-MDM4 axis could...
...with greater sensitivity to the PRMT5 inhibitor GSK3326595. Treatment with GSK3326595 or an shRNA against MDM4...
...through Phase II testing for other cancers. TARGET/MARKER/PATHWAY: Protein arginine methyltransferase 5 (PRMT5); Mdm4 p53 binding protein homolog (MDM4; MDMX...
BioCentury | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...
BioCentury | May 24, 2019
Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

FDA's ODAC may have given the thumbs down to Daiichi’s quizartinib, but a stocked pipeline and another ongoing trial of the candidate suggest it’s more of a hiccup than a hurdle in the Japanese pharma’s...
BioCentury | Jan 23, 2019
Distillery Therapeutics

Cancer

INDICATION: Leukemia; cancer Cell culture and mouse studies identified an MDM2 protein degrader that could help treat leukemia and other cancers. Chemical synthesis and testing of analogs of an MDM2 inhibitor tool compound linked to...
Items per page:
1 - 10 of 106